<- Go Home
Island Pharmaceuticals Limited
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Market Cap
AUD 134.6M
Volume
474.8K
Cash and Equivalents
AUD 6.9M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-AUD 2.0M
Profit Margin
3159.34%
52 Week High
AUD 0.63
52 Week Low
AUD 0.18
Dividend
N/A
Price / Book Value
17.11
Price / Earnings
-14.43
Price / Tangible Book Value
19.22
Enterprise Value
AUD 127.8M
Enterprise Value / EBITDA
N/A
Operating Income
-AUD 7.4M
Return on Equity
130.31%
Return on Assets
-74.67
Cash and Short Term Investments
AUD 6.9M
Debt
N/A
Equity
AUD 7.2M
Revenue
AUD 62.9K
Unlevered FCF
-AUD 2.3M
Sector
Pharmaceuticals
Category
N/A